Compare CALY & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CALY | TARS |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | United States |
| Employees | 28000 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | N/A | 2020 |
| Metric | CALY | TARS |
|---|---|---|
| Price | $17.06 | $62.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $16.50 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.5M | 475.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $9.70 | $56.43 |
| Revenue Next Year | $3.01 | $30.19 |
| P/E Ratio | $64.24 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $12.26 | $38.51 |
| 52 Week High | $18.00 | $85.25 |
| Indicator | CALY | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 64.38 | 53.10 |
| Support Level | $14.20 | $61.24 |
| Resistance Level | $18.00 | $67.24 |
| Average True Range (ATR) | 0.63 | 2.72 |
| MACD | 0.17 | 0.44 |
| Stochastic Oscillator | 79.82 | 76.83 |
Callaway Golf Co is a golf equipment, gear and apparel company with a portfolio of world-wide brands, including Callaway Golf, Odyssey, TravisMathew, and OGIO. Callaway designs, manufactures, and sells high-performance golf clubs, golf balls, apparel, bags, and other accessories-setting the standard for performance in the game of golf. The company has two operating and reportable business segments: Golf Equipment and Apparel, Gear and Other. Geographically, the company operates in United States, Europe, Asia, and Rest of World, of which it derives maximum revenue from United States.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.